HemaCare Will Attend Annual CAR-TCR Conference in Boston

HemaCare Corporation (OTCBB: HEMA), announced today that it will be attending the annual CAR-TCR conference September 5-8, 2017, in Boston, MA. The conference is focused on the development and commercialization of cell therapy that uses the immune system to fight cancer and other diseases. CAR-TCR stands for Chimeric Antigen Receptor (CAR) and T Cell Receptor (TCR), which are engineered receptors on immune effector cells that can be directed to specifically bind to and destroy target cells, such as cancer. Development of CAR-TCR therapy represents the newest approach to cancer therapy, and requires new technology and strategies for manufacturing human cells as living drugs. Over 500 attendees, including business leaders from large pharmaceutical and biotechnology companies and academic clinical and research leaders will discuss the latest clinical trials and strategies for expanding access to this new technology.

“Many of the CAR-T focused companies have historically sourced their process development material from HemaCare. This conference presents a great opportunity for HemaCare to meet with current and future customers to collaborate on the enhanced support HemaCare provides as we continue expanding our cGMP capabilities,” said Pete van der Wal, HemaCare’s Chief Executive Officer. “As a provider of primary human cells for biomedical research and cell therapy process development, we look forward to enabling the emerging needs of the industry as it rapidly moves into an advanced stage of development.”

About Us

HemaCare Corporation is a provider of human blood products and services in support of the rapidly expanding field of immune therapy, including stem cell therapy. Our expertise has evolved through 39 years in the business of blood collection, processing and storage. In addition, we have established a robust donor recruitment and management system which supports an extensive registry of well-characterized repeat donors. HemaCare’s controlled procedures ensure a readily available inventory of high-quality, consistent and selectable primary human cells and biological products for advanced biomedical research. Our customers are engaged in basic research and development of clinical therapies that are designed to manipulate the immune system for treatment and cure of cancer, degenerative diseases and immune and genetic disorders. HemaCare’s products and services address several key markets, including immune therapy research, cell manufacturing for clinical therapy, and clinical laboratory instrument development. We specialize in custom cell collections for customers who may require donors with specific attributes (phenotypic or disease state, for example), or sub-sets of immune cells that can be selected in our laboratory using the latest technology. HemaCare’s products and services address all stages of cell therapy development, from basic biological research in academic institutions to pharmaceutical cell development in large drug companies.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170823005353/en/